Drug and radiation combination to save the bladder in HER2-positive bladder cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests a combination of two drugs (toripalimab and RC48-ADC) plus radiation therapy to treat bladder cancer while keeping the bladder intact. It aims to see if this approach can control the cancer without needing to remove the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and able to do most of your daily activities without help.
- Your bladder cancer must have grown into the muscle layer (but not spread to lymph nodes or other organs).
- Your tumor must test positive for a protein called HER2 (at any level: 1+, 2+, or 3+).
- You must not have had immunotherapy before, and you must not have active hepatitis B, C, or HIV.
- You must be willing to use effective birth control during the study and for 12 months after treatment.
- You must be able to have radiation therapy along with the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
This trial tests a combination of two drugs—vedisertib (RC48) and toripalimab—for people with bladder cancer that has invaded the muscle but hasn't spread. The goal is to preserve the bladder while treating the cancer.
This trial tests a combination of two medications, disitamab vedotin and toripalimab, to treat bladder cancer that has grown into the muscle layer of the bladder. The goal is to see if this treatment can save the bladder while effectively fighting the cancer.
This study tests a combination of a targeted drug (disitamab vedotin), an immunotherapy drug (PD-1 inhibitor), and radiation therapy as a way to treat bladder cancer without removing the bladder. It is for people whose cancer has grown into the bladder muscle but hasn't spread to other parts of the body, and whose tumor shows high HER2 levels.
This trial tests a new combination of two drugs before bladder removal surgery for patients with HER2-positive muscle-invasive bladder cancer. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of an antibody-drug conjugate (RC48) plus chemotherapy (gemcitabine) given before bladder removal surgery. It is for people with HER2-positive bladder cancer that has grown into the muscle layer.
Hear when a new Muscle Invasive Bladder Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.